Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Phio Pharmaceuticals Corp (PHIO)

Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,784
  • Shares Outstanding, K 2,443
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,480 K
  • 60-Month Beta 1.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.22
Trade PHIO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.76
  • Most Recent Earnings $-1.14 on 11/09/23
  • Latest Earnings Date 03/27/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.30
  • Number of Estimates 1
  • High Estimate -1.30
  • Low Estimate -1.30
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7010 +3.58%
on 03/22/24
1.1500 -36.86%
on 03/06/24
-0.2314 (-24.17%)
since 02/27/24
3-Month
0.5000 +45.22%
on 01/26/24
1.1500 -36.86%
on 03/06/24
-0.0249 (-3.32%)
since 12/27/23
52-Week
0.5000 +45.22%
on 01/26/24
12.2700 -94.08%
on 04/18/23
-4.9539 (-87.22%)
since 03/27/23

Most Recent Stories

More News
Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLâ„¢ RNAi platform technology is...

PHIO : 0.7261 (-0.53%)
Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLâ„¢ RNAi platform technology is...

PHIO : 0.7261 (-0.53%)
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYLâ„¢ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLâ„¢ RNAi platform technology is...

PHIO : 0.7261 (-0.53%)
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLâ„¢ RNAi platform technology is...

PHIO : 0.7261 (-0.53%)
Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLâ„¢ RNAi platform technology is...

PHIO : 0.7261 (-0.53%)
Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLâ„¢ RNAi platform technology is...

PHIO : 0.7261 (-0.53%)
Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLâ„¢ RNAi platform technology is...

PHIO : 0.7261 (-0.53%)
Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLâ„¢ RNAi platform technology is...

PHIO : 0.7261 (-0.53%)
Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLâ„¢ RNAi platform technology is...

PHIO : 0.7261 (-0.53%)
Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLâ„¢ RNAi platform technology is...

PHIO : 0.7261 (-0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Phio Pharmaceuticals Corp is focused on developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform. The Company's pipeline consists of RXI-762 and RXI-804 which are in clinical stage. Phio Pharmaceuticals Corp, formerly known as RXi Pharmaceuticals Corporation,...

See More

Key Turning Points

3rd Resistance Point 0.8041
2nd Resistance Point 0.7820
1st Resistance Point 0.7541
Last Price 0.7261
1st Support Level 0.7041
2nd Support Level 0.6820
3rd Support Level 0.6541

See More

52-Week High 12.2700
Fibonacci 61.8% 7.7739
Fibonacci 50% 6.3850
Fibonacci 38.2% 4.9961
Last Price 0.7261
52-Week Low 0.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar